Media stories about Rewalk Robotics (NASDAQ:RWLK) have been trending somewhat positive recently, AlphaOne reports. AlphaOne, a unit of Accern, ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rewalk Robotics earned a media sentiment score of 0.05 on AlphaOne’s scale. AlphaOne also assigned news articles about the medical device company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Alpha One’s rankings:
- The Oppenheimer Holdings Inc. Reaffirms Outperform Rating for Rewalk Robotics Ltd (RWLK) – BangaloreWeekly (bangaloreweekly.com)
- The Rewalk Robotics (RWLK) Earns News Sentiment Rating of 0.46 – BangaloreWeekly (bangaloreweekly.com)
- Share Activity Lifted for Rewalk Robotics Ltd (RWLK) in Session – Melville Review (melvillereview.com)
- The Rewalk Robotics Ltd (RWLK) Posts Earnings Results, Beats Estimates By $0.10 EPS – BangaloreWeekly (bangaloreweekly.com)
Rewalk Robotics (NASDAQ:RWLK) last released its quarterly earnings data on Thursday, May 4th. The medical device company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.10. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.45 million. Rewalk Robotics had a negative net margin of 560.49% and a negative return on equity of 248.47%. The business’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.48) EPS.
RWLK has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Rewalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Thursday, May 11th. Barclays PLC downgraded shares of Rewalk Robotics from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $2.50 to $1.50 in a research report on Monday, April 3rd. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Rewalk Robotics in a research report on Wednesday, May 10th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Rewalk Robotics currently has a consensus rating of “Buy” and a consensus target price of $5.40.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2568234/rewalk-robotics-rwlk-earning-somewhat-positive-media-coverage-study-finds.html.
Rewalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for Rewalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.